interactions:
- request:
    body: null
    headers:
      Connection: [close]
      Host: [www.uniprot.org]
      User-Agent: [Python-urllib/3.5]
    method: GET
    uri: http://www.uniprot.org/uniprot/P06858.txt
  response:
    body: {string: "ID   LIPL_HUMAN              Reviewed;         475 AA.\nAC   P06858;
        B2R5T9; Q16282; Q16283; Q96FC4;\nDT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.\nDT
        \  01-JAN-1988, sequence version 1.\nDT   10-MAY-2017, entry version 210.\nDE
        \  RecName: Full=Lipoprotein lipase;\nDE            Short=LPL;\nDE            EC=3.1.1.34
        {ECO:0000269|PubMed:11342582, ECO:0000269|PubMed:27578112};\nDE   Flags: Precursor;\nGN
        \  Name=LPL; Synonyms=LIPD;\nOS   Homo sapiens (Human).\nOC   Eukaryota; Metazoa;
        Chordata; Craniata; Vertebrata; Euteleostomi;\nOC   Mammalia; Eutheria; Euarchontoglires;
        Primates; Haplorrhini;\nOC   Catarrhini; Hominidae; Homo.\nOX   NCBI_TaxID=9606;\nRN
        \  [1]\nRP   NUCLEOTIDE SEQUENCE [MRNA].\nRX   PubMed=3823907; DOI=10.1126/science.3823907;\nRA
        \  Wion K.L., Kirchgessner T.G., Lusis A.J., Schotz M.C., Lawn R.M.;\nRT   \"Human
        lipoprotein lipase complementary DNA sequence.\";\nRL   Science 235:1638-1641(1987).\nRN
        \  [2]\nRP   NUCLEOTIDE SEQUENCE [MRNA].\nRC   TISSUE=Placenta;\nRX   PubMed=2701938;
        DOI=10.1093/nar/17.6.2351;\nRA   Gotoda T., Senda M., Gamou T., Furuichi Y.,
        Oka K.;\nRT   \"Nucleotide sequence of human cDNA coding for a lipoprotein
        lipase\nRT   (LPL) cloned from placental cDNA library.\";\nRL   Nucleic Acids
        Res. 17:2351-2352(1989).\nRN   [3]\nRP   NUCLEOTIDE SEQUENCE [MRNA].\nRX   PubMed=2243796;
        DOI=10.1093/nar/18.21.6436;\nRA   Takagi A., Ikeda Y., Yamamoto A.;\nRT   \"DNA
        sequence of lipoprotein lipase cDNA cloned from human monocytic\nRT   leukemia
        THP-1 cells.\";\nRL   Nucleic Acids Res. 18:6436-6436(1990).\nRN   [4]\nRP
        \  NUCLEOTIDE SEQUENCE [GENOMIC DNA].\nRX   PubMed=1537564; DOI=10.1016/0378-1119(92)90658-C;\nRA
        \  Chuat J.-C., Raisonnier A., Etienne J., Galibert F.;\nRT   \"The lipoprotein
        lipase-encoding human gene: sequence from intron-6 to\nRT   intron-9 and presence
        in intron-7 of a 40-million-year-old Alu\nRT   sequence.\";\nRL   Gene 110:257-261(1992).\nRN
        \  [5]\nRP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT SER-318.\nRA
        \  Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,\nRA
        \  Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,\nRA
        \  Phelan M., Farmer A.;\nRT   \"Cloning of human full-length CDSs in BD Creator(TM)
        system donor\nRT   vector.\";\nRL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ
        databases.\nRN   [6]\nRP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].\nRC   TISSUE=Cerebellum;\nRX
        \  PubMed=14702039; DOI=10.1038/ng1285;\nRA   Ota T., Suzuki Y., Nishikawa
        T., Otsuki T., Sugiyama T., Irie R.,\nRA   Wakamatsu A., Hayashi K., Sato
        H., Nagai K., Kimura K., Makita H.,\nRA   Sekine M., Obayashi M., Nishi T.,
        Shibahara T., Tanaka T., Ishii S.,\nRA   Yamamoto J., Saito K., Kawai Y.,
        Isono Y., Nakamura Y., Nagahari K.,\nRA   Murakami K., Yasuda T., Iwayanagi
        T., Wagatsuma M., Shiratori A.,\nRA   Sudo H., Hosoiri T., Kaku Y., Kodaira
        H., Kondo H., Sugawara M.,\nRA   Takahashi M., Kanda K., Yokoi T., Furuya
        T., Kikkawa E., Omura Y.,\nRA   Abe K., Kamihara K., Katsuta N., Sato K.,
        Tanikawa M., Yamazaki M.,\nRA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa
        K., Fujimori K.,\nRA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba
        Y., Ishida S.,\nRA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta
        T., Kusano J.,\nRA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O.,
        Nomura Y.,\nRA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose
        N.,\nRA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,\nRA   Yoshikawa
        Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,\nRA   Moriya S., Momiyama
        H., Satoh N., Takami S., Terashima Y., Suzuki O.,\nRA   Nakagawa S., Senoh
        A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,\nRA   Hishigaki H., Watanabe
        T., Sugiyama A., Takemoto M., Kawakami B.,\nRA   Yamazaki M., Watanabe K.,
        Kumagai A., Itakura S., Fukuzumi Y.,\nRA   Fujimori Y., Komiyama M., Tashiro
        H., Tanigami A., Fujiwara T.,\nRA   Ono T., Yamada K., Fujii Y., Ozaki K.,
        Hirao M., Ohmori Y.,\nRA   Kawabata A., Hikiji T., Kobatake N., Inagaki H.,
        Ikema Y., Okamoto S.,\nRA   Okitani R., Kawakami T., Noguchi S., Itoh T.,
        Shigeta K., Senba T.,\nRA   Matsumura K., Nakajima Y., Mizuno T., Morinaga
        M., Sasaki M.,\nRA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,\nRA
        \  Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,\nRA
        \  Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,\nRA
        \  Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;\nRT   \"Complete
        sequencing and characterization of 21,243 full-length human\nRT   cDNAs.\";\nRL
        \  Nat. Genet. 36:40-45(2004).\nRN   [7]\nRP   NUCLEOTIDE SEQUENCE [LARGE
        SCALE GENOMIC DNA].\nRA   Mural R.J., Istrail S., Sutton G.G., Florea L.,
        Halpern A.L.,\nRA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I.,
        Miller J.R.,\nRA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson
        B.V.,\nRA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,\nRA
        \  Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,\nRA   Kravitz
        S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,\nRA   Waterman
        M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,\nRA   Venter
        J.C.;\nRL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.\nRN   [8]\nRP
        \  NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT SER-318.\nRC   TISSUE=Brain;\nRX
        \  PubMed=15489334; DOI=10.1101/gr.2596504;\nRG   The MGC Project Team;\nRT
        \  \"The status, quality, and expansion of the NIH full-length cDNA\nRT   project:
        the Mammalian Gene Collection (MGC).\";\nRL   Genome Res. 14:2121-2127(2004).\nRN
        \  [9]\nRP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-5.\nRX   PubMed=1406652;
        DOI=10.1128/MCB.12.10.4622;\nRA   Enerbaeck S., Ohlsson B.G., Samuelsson L.,
        Bjursell G.;\nRT   \"Characterization of the human lipoprotein lipase (LPL)
        promoter:\nRT   evidence of two cis-regulatory regions, LP-alpha and LP-beta,
        of\nRT   importance for the differentiation-linked induction of the LPL gene\nRT
        \  during adipogenesis.\";\nRL   Mol. Cell. Biol. 12:4622-4633(1992).\nRN
        \  [10]\nRP   PROTEIN SEQUENCE OF 28-44, AND SUBCELLULAR LOCATION.\nRC   TISSUE=Milk;\nRX
        \  PubMed=2340307; DOI=10.1016/0005-2760(90)90213-H;\nRA   Zechner R.;\nRT
        \  \"Rapid and simple isolation procedure for lipoprotein lipase from\nRT
        \  human milk.\";\nRL   Biochim. Biophys. Acta 1044:20-25(1990).\nRN   [11]\nRP
        \  HEPARIN-BINDING, CATALYTIC ACTIVITY, AND FUNCTION.\nRX   PubMed=11342582;
        DOI=10.1172/JCI11774;\nRA   Lutz E.P., Merkel M., Kako Y., Melford K., Radner
        H., Breslow J.L.,\nRA   Bensadoun A., Goldberg I.J.;\nRT   \"Heparin-binding
        defective lipoprotein lipase is unstable and causes\nRT   abnormalities in
        lipid delivery to tissues.\";\nRL   J. Clin. Invest. 107:1183-1192(2001).\nRN
        \  [12]\nRP   INTERACTION WITH GPIHBP1.\nRX   PubMed=17997385; DOI=10.1016/j.bbalip.2007.10.005;\nRA
        \  Gin P., Beigneux A.P., Davies B., Young M.F., Ryan R.O., Bensadoun A.,\nRA
        \  Fong L.G., Young S.G.;\nRT   \"Normal binding of lipoprotein lipase, chylomicrons,
        and apo-AV to\nRT   GPIHBP1 containing a G56R amino acid substitution.\";\nRL
        \  Biochim. Biophys. Acta 1771:1464-1468(2007).\nRN   [13]\nRP   GLYCOSYLATION
        [LARGE SCALE ANALYSIS] AT ASN-70.\nRC   TISSUE=Milk;\nRX   PubMed=18780401;
        DOI=10.1002/pmic.200701057;\nRA   Picariello G., Ferranti P., Mamone G., Roepstorff
        P., Addeo F.;\nRT   \"Identification of N-linked glycoproteins in human milk
        by hydrophilic\nRT   interaction liquid chromatography and mass spectrometry.\";\nRL
        \  Proteomics 8:3833-3847(2008).\nRN   [14]\nRP   3D-STRUCTURE MODELING.\nRX
        \  PubMed=8308035;\nRA   van Tilbeurgh H., Roussel A., Lalouel J.-M., Cambillau
        C.;\nRT   \"Lipoprotein lipase. Molecular model based on the pancreatic lipase
        X-\nRT   ray structure: consequences for heparin binding and catalysis.\";\nRL
        \  J. Biol. Chem. 269:4626-4633(1994).\nRN   [15]\nRP   INTERACTION WITH SEL1L
        AND LMF1.\nRX   PubMed=25066055; DOI=10.1016/j.cmet.2014.06.015;\nRA   Sha
        H., Sun S., Francisco A.B., Ehrhardt N., Xue Z., Liu L.,\nRA   Lawrence P.,
        Mattijssen F., Guber R.D., Panhwar M.S., Brenna J.T.,\nRA   Shi H., Xue B.,
        Kersten S., Bensadoun A., Peterfy M., Long Q., Qi L.;\nRT   \"The ER-associated
        degradation adaptor protein Sel1L regulates LPL\nRT   secretion and lipid
        metabolism.\";\nRL   Cell Metab. 20:458-470(2014).\nRN   [16]\nRP   REVIEW
        ON VARIANTS.\nRA   Hayden M.R., Ma Y., Brunzell J., Henderson H.E.;\nRT   \"Genetic
        variants affecting human lipoprotein and hepatic lipases.\";\nRL   Curr. Opin.
        Lipidol. 2:104-109(1991).\nRN   [17]\nRP   VARIANT LPL DEFICIENCY THR-271,
        AND INVOLVEMENT IN LPL.\nRX   PubMed=2121025;\nRA   Hata A., Emi M., Luc G.,
        Basdevant A., Gambert P., Iverius P.-H.,\nRA   Lalouel J.-M.;\nRT   \"Compound
        heterozygote for lipoprotein lipase deficiency: Ser-->Thr244\nRT   and transition
        in 3' splice site of intron 2 (AG-->AA) in the\nRT   lipoprotein lipase gene.\";\nRL
        \  Am. J. Hum. Genet. 47:721-726(1990).\nRN   [18]\nRP   VARIANT LPL DEFICIENCY
        GLU-215.\nRX   PubMed=1969408;\nRA   Emi M., Wilson D.E., Iverius P.H., Wiu
        L., Hata A., Hegele R.,\nRA   Williams R.R., Lalouel J.-M.;\nRT   \"Missense
        mutation (Gly-->Glu188) of human lipoprotein lipase\nRT   imparting functional
        deficiency.\";\nRL   J. Biol. Chem. 265:5910-5916(1990).\nRN   [19]\nRP   VARIANT
        LPL DEFICIENCY GLU-215.\nRX   PubMed=1975597; DOI=10.1172/JCI114769;\nRA   Monsalve
        M.V., Henderson H., Roederer G., Julien P., Deeb S.,\nRA   Kastelein J.J.P.,
        Peritz L., Devlin R., Bruin T., Murthy M.R.V.,\nRA   Gagne C., Davignon J.,
        Lupien P.J., Brunzell J.D., Hayden M.R.;\nRT   \"A missense mutation at codon
        188 of the human lipoprotein lipase gene\nRT   is a frequent cause of lipoprotein
        lipase deficiency in persons of\nRT   different ancestries.\";\nRL   J. Clin.
        Invest. 86:728-734(1990).\nRN   [20]\nRP   VARIANT LPL DEFICIENCY THR-203.\nRX
        \  PubMed=2110364; DOI=10.1073/pnas.87.9.3474;\nRA   Beg O.U., Meng M.S.,
        Skarlatos S.I., Previato L., Brunzell J.D.,\nRA   Brewer H.B. Jr., Fojo S.S.;\nRT
        \  \"Lipoprotein lipase Bethesda: a single amino acid substitution (Ala-\nRT
        \  176-->Thr) leads to abnormal heparin binding and loss of enzymic\nRT   activity.\";\nRL
        \  Proc. Natl. Acad. Sci. U.S.A. 87:3474-3478(1990).\nRN   [21]\nRP   VARIANTS
        LPL DEFICIENCY THR-221 AND HIS-270.\nRX   PubMed=1702428;\nRA   Dichek H.L.,
        Fojo S.S., Beg O.U., Skarlatos S.I., Brunzell J.D.,\nRA   Cutler G.B. Jr.,
        Brewer H.B. Jr.;\nRT   \"Identification of two separate allelic mutations
        in the lipoprotein\nRT   lipase gene of a patient with the familial hyperchylomicronemia\nRT
        \  syndrome.\";\nRL   J. Biol. Chem. 266:473-477(1991).\nRN   [22]\nRP   VARIANT
        LPL DEFICIENCY GLY-183.\nRX   PubMed=1907278;\nRA   Faustinella F., Chang
        A., van Biervliet J.P., Rosseneu M.,\nRA   Vinaimont N., Smith L.C., Chen
        S.-H., Chan L.;\nRT   \"Catalytic triad residue mutation (Asp156-->Gly) causing
        familial\nRT   lipoprotein lipase deficiency. Co-inheritance with a nonsense
        mutation\nRT   (Ser447-->Ter) in a Turkish family.\";\nRL   J. Biol. Chem.
        266:14418-14424(1991).\nRN   [23]\nRP   VARIANT LPL DEFICIENCY GLU-169.\nRX
        \  PubMed=2010533; DOI=10.1172/JCI115114;\nRA   Ameis D., Kobayashi J., Davis
        R.C., Ben-Zeev O., Malloy M.J.,\nRA   Kane J.P., Lee G., Wong H., Havel R.J.,
        Schotz M.C.;\nRT   \"Familial chylomicronemia (type I hyperlipoproteinemia)
        due to a\nRT   single missense mutation in the lipoprotein lipase gene.\";\nRL
        \  J. Clin. Invest. 87:1165-1170(1991).\nRN   [24]\nRP   VARIANT LPL DEFICIENCY
        THR-221.\nRX   PubMed=1674945; DOI=10.1172/JCI115229;\nRA   Henderson H.E.,
        Ma Y., Hassan F., Monsalve M.V., Marais A.D.,\nRA   Winkler F., Gubernator
        K., Peterson J., Brunzell J.D., Hayden M.R.;\nRT   \"Amino acid substitution
        (Ile194-->Thr) in exon 5 of the lipoprotein\nRT   lipase gene causes lipoprotein
        lipase deficiency in three unrelated\nRT   probands. Support for a multicentric
        origin.\";\nRL   J. Clin. Invest. 87:2005-2011(1991).\nRN   [25]\nRP   VARIANTS
        LPL DEFICIENCY GLU-231 AND HIS-270, AND CHARACTERIZATION OF\nRP   VARIANTS
        LPL DEFICIENCY GLU-231 AND HIS-270.\nRX   PubMed=1752947; DOI=10.1172/JCI115507;\nRA
        \  Gotoda T., Yamada N., Kawamura M., Kozaki K., Mori N., Ishibashi S.,\nRA
        \  Shimano H., Takaku F., Yazaki Y., Furuichi Y., Murase T.;\nRT   \"Heterogeneous
        mutations in the human lipoprotein lipase gene in\nRT   patients with familial
        lipoprotein lipase deficiency.\";\nRL   J. Clin. Invest. 88:1856-1864(1991).\nRN
        \  [26]\nRP   VARIANT LPL DEFICIENCY LEU-234.\nRX   PubMed=2038366; DOI=10.1056/NEJM199106203242502;\nRA
        \  Ma Y., Henderson H.E., Ven Murthy M.R., Roederer G., Monsalve M.V.,\nRA
        \  Clarke L.A., Normand T., Julien P., Gagne C., Lambert M., Davignon J.,\nRA
        \  Lupien P.J., Brunzell J., Hayden M.R.;\nRT   \"A mutation in the human
        lipoprotein lipase gene as the most common\nRT   cause of familial chylomicronemia
        in French Canadians.\";\nRL   N. Engl. J. Med. 324:1761-1766(1991).\nRN   [27]\nRP
        \  VARIANT LPL DEFICIENCY ARG-113.\nRX   PubMed=1598907;\nRA   Ishimura-Oka
        K., Faustinella F., Kihara S., Smith L.C., Oka K.,\nRA   Chan L.;\nRT   \"A
        missense mutation (Trp86-->Arg) in exon 3 of the lipoprotein lipase\nRT   gene:
        a cause of familial chylomicronemia.\";\nRL   Am. J. Hum. Genet. 50:1275-1280(1992).\nRN
        \  [28]\nRP   VARIANT LPL DEFICIENCY ARG-184.\nRX   PubMed=1521525; DOI=10.1111/j.1432-1033.1992.tb17182.x;\nRA
        \  Bruin T., Kastelein J.J., van Diermen D.E., Ma Y., Henderson H.E.,\nRA
        \  Stuyt P.M., Stalenhoef A.F.H., Sturk A., Brunzell J.D., Hayden M.R.;\nRT
        \  \"A missense mutation Pro157Arg in lipoprotein lipase (LPLNijmegen)\nRT
        \  resulting in loss of catalytic activity.\";\nRL   Eur. J. Biochem. 208:267-272(1992).\nRN
        \  [29]\nRP   VARIANT LPL DEFICIENCY ASN-277.\nRX   PubMed=1639392; DOI=10.1016/0888-7543(92)90136-G;\nRA
        \  Ma Y., Wilson B.I., Bijvoet S., Henderson H.E., Cramb E., Roederer G.,\nRA
        \  Ven Murthy M.R., Julien P., Bakker H.D., Kastelein J.J.,\nRA   Brunzell
        J.D., Hayden M.R.;\nRT   \"A missense mutation (Asp250-->Asn) in exon 6 of
        the human lipoprotein\nRT   lipase gene causes chylomicronemia in patients
        of different\nRT   ancestries.\";\nRL   Genomics 13:649-653(1992).\nRN   [30]\nRP
        \  VARIANTS LPL DEFICIENCY ASN-183; GLY-183 AND SER-243.\nRX   PubMed=1730727;\nRA
        \  Ma Y.H., Bruin T., Tuzgol S., Wilson B.I., Roederer G., Liu M.S.,\nRA   Davignon
        J., Kastelein J.J., Brunzell J.D., Hayden M.R.;\nRT   \"Two naturally occurring
        mutations at the first and second bases of\nRT   codon aspartic acid 156 in
        the proposed catalytic triad of human\nRT   lipoprotein lipase. In vivo evidence
        that aspartic acid 156 is\nRT   essential for catalysis.\";\nRL   J. Biol.
        Chem. 267:1918-1923(1992).\nRN   [31]\nRP   CHARACTERIZATION OF VARIANTS LPL
        DEFICIENCY ASN-183 AND GLY-183, AND\nRP   MUTAGENESIS OF SER-159 AND HIS-268.\nRX
        \  PubMed=1371284;\nRA   Emmerich J., Beg O.U., Peterson J., Previato L.,
        Brunzell J.D.,\nRA   Brewer H.B. Jr., Santamarina-Fojo S.;\nRT   \"Human lipoprotein
        lipase. Analysis of the catalytic triad by site-\nRT   directed mutagenesis
        of Ser-132, Asp-156, and His-241.\";\nRL   J. Biol. Chem. 267:4161-4165(1992).\nRN
        \  [32]\nRP   VARIANT LPL DEFICIENCY GLU-222.\nRX   PubMed=1400331;\nRA   Hata
        A., Ridinger D.N., Sutherland S.D., Emi M., Kwong L.K.,\nRA   Shuhua J., Lubbers
        A., Guy-Grand B., Basdevant A., Iverius P.H.,\nRA   Wilson D.E., Lalouel J.-M.;\nRT
        \  \"Missense mutations in exon 5 of the human lipoprotein lipase gene.\nRT
        \  Inactivation correlates with loss of dimerization.\";\nRL   J. Biol. Chem.
        267:20132-20139(1992).\nRN   [33]\nRP   VARIANTS LPL DEFICIENCY GLU-215; HIS-270
        AND ASN-277.\nRX   PubMed=1619366;\nRA   Ishimura-Oka K., Semenkovich C.F.,
        Faustinella F., Goldberg I.J.,\nRA   Shachter N., Smith L.C., Coleman T.,
        Hide W.A., Brown W.V., Oka K.;\nRT   \"A missense (Asp250-->Asn) mutation
        in the lipoprotein lipase gene in\nRT   two unrelated families with familial
        lipoprotein lipase deficiency.\";\nRL   J. Lipid Res. 33:745-754(1992).\nRN
        \  [34]\nRP   VARIANTS LPL DEFICIENCY ARG-113; ARG-163; GLU-215; THR-221 AND\nRP
        \  SER-232.\nRX   PubMed=1479292;\nRA   Reina M., Brunzell J.D., Deeb S.S.;\nRT
        \  \"Molecular basis of familial chylomicronemia: mutations in the\nRT   lipoprotein
        lipase and apolipoprotein C-II genes.\";\nRL   J. Lipid Res. 33:1823-1832(1992).\nRN
        \  [35]\nRP   VARIANT LPL DEFICIENCY THR-361.\nRX   PubMed=8096693; DOI=10.1006/bbrc.1993.1323;\nRA
        \  Kobayashi J., Sasaki N., Tashiro J., Inadera H., Saito Y., Yoshida S.;\nRT
        \  \"A missense mutation (Ala334-->Thr) in exon 7 of the lipoprotein\nRT   lipase
        gene in a case with type I hyperlipidemia.\";\nRL   Biochem. Biophys. Res.
        Commun. 191:1046-1054(1993).\nRN   [36]\nRP   VARIANT LPL DEFICIENCY GLU-207.\nRX
        \  PubMed=8288243; DOI=10.1006/geno.1993.1481;\nRA   Haubenwallner S., Horl
        G., Shachter N.S., Presta E., Fried S.K.,\nRA   Hofler G., Kostner G.M., Breslow
        J.L., Zechner R.;\nRT   \"A novel missense mutation in the gene for lipoprotein
        lipase\nRT   resulting in a highly conservative amino acid substitution\nRT
        \  (Asp180-->Glu) causes familial chylomicronemia (type I\nRT   hyperlipoproteinemia).\";\nRL
        \  Genomics 18:392-396(1993).\nRN   [37]\nRP   VARIANT LPL DEFICIENCY CYS-199.\nRX
        \  PubMed=8486765; DOI=10.1172/JCI116414;\nRA   Ma Y., Liu M.-S., Ginzinger
        D., Frohlich J., Brunzell J.D.,\nRA   Hayden M.R.;\nRT   \"Gene-environment
        interaction in the conversion of a mild-to-severe\nRT   phenotype in a patient
        homozygous for a Ser172-->Cys mutation in the\nRT   lipoprotein lipase gene.\";\nRL
        \  J. Clin. Invest. 91:1953-1958(1993).\nRN   [38]\nRP   VARIANT LPL DEFICIENCY
        SER-102.\nRX   PubMed=8325986; DOI=10.1172/JCI116551;\nRA   Wilson D.E., Hata
        A., Kwong L.K., Lingam A., Shuhua J., Ridinger D.N.,\nRA   Yeager C., Kaltenborn
        K.C., Iverius P.-H., Lalouel J.-M.;\nRT   \"Mutations in exon 3 of the lipoprotein
        lipase gene segregating in a\nRT   family with hypertriglyceridemia, pancreatitis,
        and non-insulin-\nRT   dependent diabetes.\";\nRL   J. Clin. Invest. 92:203-211(1993).\nRN
        \  [39]\nRP   VARIANT LPL DEFICIENCY SER-181.\nRX   PubMed=8301230;\nRA   Bruin
        T., Tuzgol S., van Diermen D.E., Hoogerbrugge-Van der Linden N.,\nRA   Brunzell
        J.D., Hayden M.R., Kastelein J.J.;\nRT   \"Recurrent pancreatitis and chylomicronemia
        in an extended Dutch\nRT   kindred is caused by a Gly154-->Ser substitution
        in lipoprotein\nRT   lipase.\";\nRL   J. Lipid Res. 34:2109-2119(1993).\nRN
        \  [40]\nRP   VARIANT LPL DEFICIENCY VAL-392.\nRX   PubMed=8135797; DOI=10.1006/bbrc.1994.1266;\nRA
        \  Chimienti G.P.G., Resta F., di Perma V., Tarricone C., Lovecchio M.,\nRA
        \  Collacicco A.M., Capurso A.;\nRT   \"A new Italian case of lipoprotein
        lipase deficiency: a Leu365-> Val\nRT   change resulting in loss of enzyme
        activity.\";\nRL   Biochem. Biophys. Res. Commun. 199:570-576(1994).\nRN   [41]\nRP
        \  VARIANT LPL DEFICIENCY SER-70, AND CHARACTERIZATION OF VARIANT LPL\nRP
        \  DEFICIENCY SER-70.\nRX   PubMed=7999071; DOI=10.1006/bbrc.1994.2694;\nRA
        \  Kobayashi J., Inadera H., Fujita Y., Talley G., Morisaki N.,\nRA   Yoshida
        S., Saito Y., Fojo S.S., Brewer H.B. Jr.;\nRT   \"A naturally occurring mutation
        at the second base of codon asparagine\nRT   43 in the proposed N-linked glycosylation
        site of human lipoprotein\nRT   lipase: in vivo evidence that asparagine 43
        is essential for catalysis\nRT   and secretion.\";\nRL   Biochem. Biophys.
        Res. Commun. 205:506-515(1994).\nRN   [42]\nRP   VARIANTS LPL DEFICIENCY HIS-270
        AND CYS-270.\nRX   PubMed=7906986; DOI=10.1002/humu.1380030109;\nRA   Ma Y.,
        Liu M.-S., Chitayat D., Bruin T., Beisiegel U., Benlian P.,\nRA   Foubert
        L., De Gennes J.L., Funke H., Forsythe I., Blaichman S.,\nRA   Papanikolaou
        M., Erkelens D.W., Kastelein J., Brunzell J.D.,\nRA   Hayden M.R.;\nRT   \"Recurrent
        missense mutations at the first and second base of codon\nRT   Arg243 in human
        lipoprotein lipase in patients of different\nRT   ancestries.\";\nRL   Hum.
        Mutat. 3:52-58(1994).\nRN   [43]\nRP   VARIANTS LPL DEFICIENCY LEU-96 AND
        GLU-215, AND CHARACTERIZATION OF\nRP   VARIANT LPL DEFICIENCY LEU-96.\nRX
        \  PubMed=7912254;\nRA   Bruin T., Tuzgoel S., Mulder W.J., van den Ende A.E.,
        Jansen H.,\nRA   Hayden M.R., Kastelein J.J.P.;\nRT   \"A compound heterozygote
        for lipoprotein lipase deficiency,\nRT   Val69-->Leu and Gly188-->Glu: correlation
        between in vitro LPL\nRT   activity and clinical expression.\";\nRL   J. Lipid
        Res. 35:438-445(1994).\nRN   [44]\nRP   VARIANTS LPL DEFICIENCY CYS-199; ARG-279;
        THR-288 AND SER-318, AND\nRP   CHARACTERIZATION OF VARIANTS LPL DEFICIENCY
        ARG-279 AND THR-288.\nRX   PubMed=8077845;\nRA   Ma Y., Ooi T.C., Liu M.-S.,
        Zhang H., McPherson R., Edwards A.L.,\nRA   Forsythe I.J., Frohlich J., Brunzell
        J.D., Hayden M.R.;\nRT   \"High frequency of mutations in the human lipoprotein
        lipase gene in\nRT   pregnancy-induced chylomicronemia: possible association
        with\nRT   apolipoprotein E2 isoform.\";\nRL   J. Lipid Res. 35:1066-1075(1994).\nRN
        \  [45]\nRP   VARIANT LPL DEFICIENCY VAL-437.\nRX   PubMed=7806969;\nRA   Previato
        L., Guardamagna O., Dugi K.A., Ronan R., Talley G.D.,\nRA   Santamarina-Fojo
        S., Brewer H.B. Jr.;\nRT   \"A novel missense mutation in the C-terminal domain
        of lipoprotein\nRT   lipase (Glu410-->Val) leads to enzyme inactivation and
        familial\nRT   chylomicronemia.\";\nRL   J. Lipid Res. 35:1552-1560(1994).\nRN
        \  [46]\nRP   VARIANT LPL DEFICIENCY SER-318.\nRX   PubMed=7647785; DOI=10.1038/ng0595-28;\nRA
        \  Reymer P.W.A., Gagne E., Groenemeyer B.E., Zhang H., Forsyth I.,\nRA   Jansen
        H., Seidell J.C., Kromhout D., Lie K.E., Kastelein J.J.,\nRA   Hayden M.R.;\nRT
        \  \"A lipoprotein lipase mutation (Asn291Ser) is associated with reduced\nRT
        \  HDL cholesterol levels in premature atherosclerosis.\";\nRL   Nat. Genet.
        10:28-34(1995).\nRN   [47]\nRP   VARIANT LPL DEFICIENCY TYR-445, AND CHARACTERIZATION
        OF VARIANT LPL\nRP   DEFICIENCY TYR-445.\nRX   PubMed=8858123; DOI=10.1006/bbrc.1996.1487;\nRA
        \  Henderson H.E., Hassan F., Marais D., Hayden M.R.;\nRT   \"A new mutation
        destroying disulphide bridging in the C-terminal\nRT   domain of lipoprotein
        lipase.\";\nRL   Biochem. Biophys. Res. Commun. 227:189-194(1996).\nRN   [48]\nRP
        \  VARIANT LPL DEFICIENCY SER-318, AND VARIANT ASN-36.\nRX   PubMed=8872057;
        DOI=10.1111/j.1365-2362.1996.tb02146.x;\nRA   de Bruin T.W.A., Mailly F.,
        van Barlingen H.H.J.J., Fisher R.,\nRA   Castro Cabezas M., Talmud P., Dallinga-Thie
        G.M., Humphries S.E.;\nRT   \"Lipoprotein lipase gene mutations D9N and N291S
        in four pedigrees\nRT   with familial combined hyperlipidaemia.\";\nRL   Eur.
        J. Clin. Invest. 26:631-639(1996).\nRN   [49]\nRP   VARIANTS LPL DEFICIENCY
        ASN-277 AND LYS-437.\nRX   PubMed=8956048;\nRX   DOI=10.1002/(SICI)1098-1004(1996)8:4<381::AID-HUMU16>3.0.CO;2-Z;\nRA
        \  Wiebusch H., Funke H., Bruin T., Bucher H., von Eckardstein A.,\nRA   Kastelein
        J.J.P., Assmann G.;\nRT   \"Compound heterozygosity for a known (D250N) and
        a novel (E410K)\nRT   missense mutation in the C-terminal domain of lipoprotein
        lipase\nRT   causes familial chylomicronemia.\";\nRL   Hum. Mutat. 8:381-383(1996).\nRN
        \  [50]\nRP   VARIANTS LPL DEFICIENCY GLY-190 AND GLU-215.\nRX   PubMed=8956052;\nRX
        \  DOI=10.1002/(SICI)1098-1004(1996)8:4<392::AID-HUMU20>3.0.CO;2-X;\nRA   Wiebusch
        H., Funke H., Santer R., Richter W., Assmann G.;\nRT   \"A novel missense
        (E163G) mutation in the catalytic subunit of\nRT   lipoprotein lipase causes
        familial chylomicronemia.\";\nRL   Hum. Mutat. 8:392-392(1996).\nRN   [51]\nRP
        \  VARIANT LPL DEFICIENCY HIS-289, VARIANT ASN-36, CHARACTERIZATION OF\nRP
        \  VARIANT LPL DEFICIENCY HIS-289, AND CHARACTERIZATION OF VARIANT\nRP   ASN-36.\nRX
        \  PubMed=8728326;\nRA   Rouis M., Lohse P., Dugi K.A., Lohse P., Beg O.U.,
        Ronan R.,\nRA   Talley G.D., Brunzell J.D., Santamarina-Fojo S.;\nRT   \"Homozygosity
        for two point mutations in the lipoprotein lipase (LPL)\nRT   gene in a patient
        with familial LPL deficiency: LPL(Asp9-->Asn,\nRT   Tyr262-->His).\";\nRL
        \  J. Lipid Res. 37:651-661(1996).\nRN   [52]\nRP   VARIANTS LPL DEFICIENCY
        ALA-128; GLU-215; ARG-215; CYS-270; ASN-277\nRP   AND PRO-313.\nRX   PubMed=8778602;
        DOI=10.1056/NEJM199609193351203;\nRA   Benlian P., De Gennes J.L., Foubert
        L., Zhang H., Gagne S.E.,\nRA   Hayden M.;\nRT   \"Premature atherosclerosis
        in patients with familial chylomicronemia\nRT   caused by mutations in the
        lipoprotein lipase gene.\";\nRL   N. Engl. J. Med. 335:848-854(1996).\nRN
        \  [53]\nRP   VARIANT LPL DEFICIENCY ARG-286.\nRX   PubMed=9298816;\nRX   DOI=10.1002/(SICI)1098-1004(1997)10:3<179::AID-HUMU1>3.3.CO;2-N;\nRA
        \  Foubert L., Bruin T., de Gennes J.-L., Ehrenborg E., Furioli J.,\nRA   Kastelein
        J.J., Benlian P., Hayden M.R.;\nRT   \"A single Ser259Arg mutation in the
        gene for lipoprotein lipase causes\nRT   chylomicronemia in Moroccans of Berber
        ancestry.\";\nRL   Hum. Mutat. 10:179-185(1997).\nRN   [54]\nRP   VARIANTS.\nRX
        \  PubMed=9401010;\nRX   DOI=10.1002/(SICI)1098-1004(1997)10:6<465::AID-HUMU8>3.3.CO;2-3;\nRA
        \  Mailly F., Palmen J., Muller D.P.R., Gibbs T., Lloyd J., Brunzell J.,\nRA
        \  Durrington P., Mitropoulos K., Betteridge J., Watts G., Lithell H.,\nRA
        \  Angelico F., Humphries S.E., Talmud P.J.;\nRT   \"Familial lipoprotein
        lipase (LPL) deficiency: a catalogue of LPL gene\nRT   mutations identified
        in 20 patients from the UK, Sweden, and Italy.\";\nRL   Hum. Mutat. 10:465-473(1997).\nRN
        \  [55]\nRP   VARIANTS LPL DEFICIENCY ALA-128; HIS-183; GLU-215; ARG-215;
        LEU-234;\nRP   CYS-270 AND ASN-277.\nRX   PubMed=9279761; DOI=10.1136/jmg.34.8.672;\nRA
        \  Foubert L., De Gennes J.L., Lagarde J.P., Ehrenborg E., Raisonnier A.,\nRA
        \  Girardet J.P., Hayden M.R., Benlian P.;\nRT   \"Assessment of French patients
        with LPL deficiency for French Canadian\nRT   mutations.\";\nRL   J. Med.
        Genet. 34:672-675(1997).\nRN   [56]\nRP   VARIANTS LPL DEFICIENCY THR-252
        AND HIS-270.\nRX   PubMed=9714430;\nRX   DOI=10.1002/(SICI)1096-8628(19980724)78:4<313::AID-AJMG1>3.0.CO;2-M;\nRA
        \  Henderson H.E., Bijvoet S.M., Mannens M.A.M.M., Bruin T.,\nRA   Erkelens
        D.W., Hayden M.R., Kastelein J.J.P.;\nRT   \"Ile225Thr loop mutation in the
        lipoprotein lipase (LPL) gene is a de\nRT   novo event.\";\nRL   Am. J. Med.
        Genet. 78:313-316(1998).\nRN   [57]\nRP   VARIANT LPL DEFICIENCY LYS-448,
        AND CHARACTERIZATION OF VARIANT LPL\nRP   DEFICIENCY LYS-448.\nRX   PubMed=9498099;
        DOI=10.1016/S0009-8981(97)00144-7;\nRA   Henderson H., Leisegang F., Hassan
        F., Hayden M., Marais D.;\nRT   \"A novel Glu421Lys substitution in the lipoprotein
        lipase gene in\nRT   pregnancy-induced hypertriglyceridemic pancreatitis.\";\nRL
        \  Clin. Chim. Acta 269:1-12(1998).\nRN   [58]\nRP   VARIANTS LPL DEFICIENCY
        GLU-215 AND GLY-286.\nRX   PubMed=10660334;\nRA   Evans D., Wendt D., Ahle
        S., Guerra A., Beisiegel U.;\nRT   \"Compound heterozygosity for a new (S259G)
        and a previously described\nRT   (G188E) mutation in lipoprotein lipase (LPL)
        as a cause of\nRT   chylomicronemia.\";\nRL   Hum. Mutat. 12:217-217(1998).\nRN
        \  [59]\nRP   VARIANTS LPL DEFICIENCY THR-288 AND SER-318, AND VARIANT ASN-36.\nRX
        \  PubMed=9719626; DOI=10.1006/mgme.1998.2712;\nRA   Zhang Q., Liu Y., Liu
        B.W., Fan P., Cavanna J., Galton D.J.;\nRT   \"Common genetic variants of
        lipoprotein lipase and apolipoproteins AI-\nRT   CIII that relate to coronary
        artery disease: a study in Chinese and\nRT   European subjects.\";\nRL   Mol.
        Genet. Metab. 64:177-183(1998).\nRN   [60]\nRP   VARIANT LPL DEFICIENCY SER-318,
        AND VARIANTS MET-370 AND ALA-379.\nRX   PubMed=9662394; DOI=10.1038/907;\nRA
        \  Nickerson D.A., Taylor S.L., Weiss K.M., Clark A.G., Hutchinson R.G.,\nRA
        \  Stengaerd J., Salomaa V., Vartiainen E., Boerwinkle E., Sing C.F.;\nRT
        \  \"DNA sequence diversity in a 9.7-kb region of the human lipoprotein\nRT
        \  lipase gene.\";\nRL   Nat. Genet. 19:233-240(1998).\nRN   [61]\nRP   VARIANT
        THR-427.\nRX   PubMed=10391209; DOI=10.1038/10290;\nRA   Cargill M., Altshuler
        D., Ireland J., Sklar P., Ardlie K., Patil N.,\nRA   Shaw N., Lane C.R., Lim
        E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,\nRA   Friedland L., Rolfe A.,
        Warrington J., Lipshutz R., Daley G.Q.,\nRA   Lander E.S.;\nRT   \"Characterization
        of single-nucleotide polymorphisms in coding regions\nRT   of human genes.\";\nRL
        \  Nat. Genet. 22:231-238(1999).\nRN   [62]\nRP   ERRATUM.\nRA   Cargill M.,
        Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,\nRA   Shaw N., Lane
        C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,\nRA   Friedland L.,
        Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,\nRA   Lander E.S.;\nRL   Nat.
        Genet. 23:373-373(1999).\nRN   [63]\nRP   VARIANT LPL DEFICIENCY LEU-297,
        AND CHARACTERIZATION OF VARIANT LPL\nRP   DEFICIENCY LEU-297.\nRX   PubMed=11068186;
        DOI=10.1016/S0925-4439(00)00067-3;\nRA   Takagi A., Ikeda Y., Takeda E., Yamamoto
        A.;\nRT   \"A newly identified lipoprotein lipase (LPL) gene mutation (F270L)
        in\nRT   a Japanese patient with familial LPL deficiency.\";\nRL   Biochim.
        Biophys. Acta 1502:433-446(2000).\nRN   [64]\nRP   VARIANTS LPL DEFICIENCY
        ARG-132 AND GLU-231, AND CHARACTERIZATION OF\nRP   VARIANTS LPL DEFICIENCY
        ARG-132 AND GLU-231.\nRX   PubMed=11099402; DOI=10.1042/cs0990569;\nRA   Ikeda
        Y., Goji K., Takagi A.;\nRT   \"A compound heterozygote for a novel missense
        mutation (G105R) in exon\nRT   3 and a missense mutation (D204E) in exon 5
        of the lipoprotein lipase\nRT   gene in a Japanese infant with hyperchylomicronaemia.\";\nRL
        \  Clin. Sci. 99:569-578(2000).\nRN   [65]\nRP   VARIANT LPL DEFICIENCY TRP-266.\nRX
        \  PubMed=11134145; DOI=10.1210/jcem.85.12.7069;\nRA   Hoffmann M.M., Jacob
        S., Luft D., Schmuelling R.-M., Rett K.,\nRA   Maerz W., Haering H.-U., Matthaei
        S.;\nRT   \"Type I hyperlipoproteinemia due to a novel loss of function mutation\nRT
        \  of lipoprotein lipase, Cys(239)-->Trp, associated with recurrent\nRT   severe
        pancreatitis.\";\nRL   J. Clin. Endocrinol. Metab. 85:4795-4798(2000).\nRN
        \  [66]\nRP   VARIANT LPL DEFICIENCY ASP-210, AND CHARACTERIZATION OF VARIANT
        LPL\nRP   DEFICIENCY ASP-210.\nRX   PubMed=10787434;\nRA   Hoelzl B., Kraft
        H.G., Wiebusch H., Sandhofer A., Patsch J.,\nRA   Sandhofer F., Paulweber
        B.;\nRT   \"Two novel mutations in the lipoprotein lipase gene in a family
        with\nRT   marked hypertriglyceridemia in heterozygous carriers. Potential\nRT
        \  interaction with the polymorphic marker D1S104 on chromosome 1q21-\nRT
        \  q23.\";\nRL   J. Lipid Res. 41:734-741(2000).\nRN   [67]\nRP   VARIANT
        LPL DEFICIENCY VAL-181, AND CHARACTERIZATION OF VARIANT LPL\nRP   DEFICIENCY
        VAL-181.\nRX   PubMed=11441134;\nRA   Ikeda Y., Takagi A., Nakata Y., Sera
        Y., Hyoudou S., Hamamoto K.,\nRA   Nishi Y., Yamamoto A.;\nRT   \"Novel compound
        heterozygous mutations for lipoprotein lipase\nRT   deficiency. A G-to-T transversion
        at the first position of exon 5\nRT   causing G154V missense mutation and
        a 5' splice site mutation of\nRT   intron 8.\";\nRL   J. Lipid Res. 42:1072-1081(2001).\nRN
        \  [68]\nRP   VARIANTS LPL DEFICIENCY THR-98; ILE-208; VAL-279; ARG-279; TYR-310;\nRP
        \  ARG-325 AND PHE-365, AND CHARACTERIZATION OF VARIANTS LPL DEFICIENCY\nRP
        \  THR-98; ILE-208; VAL-279; ARG-279; TYR-310; ARG-325 AND PHE-365.\nRX   PubMed=12204001;
        DOI=10.1002/humu.9054;\nRA   Chan L.Y.S., Lam C.-W., Mak Y.-T., Tomlinson
        B., Tsang M.-W., Baum L.,\nRA   Masarei J.R.L., Pang C.-P.;\nRT   \"Genotype-phenotype
        studies of six novel LPL mutations in Chinese\nRT   patients with hypertriglyceridemia.\";\nRL
        \  Hum. Mutat. 20:232-233(2002).\nRN   [69]\nRP   VARIANT LPL DEFICIENCY PHE-303,
        AND CHARACTERIZATION OF VARIANT LPL\nRP   DEFICIENCY PHE-303.\nRX   PubMed=12641539;
        DOI=10.1046/j.1365-2362.2003.01129.x;\nRA   Saika Y., Sakai N., Takahashi
        M., Maruyama T., Kihara S., Ouchi N.,\nRA   Ishigami M., Hiraoka H., Nakamura
        T., Yamashita S., Matsuzawa Y.;\nRT   \"Novel LPL mutation (L303F) found in
        a patient associated with\nRT   coronary artery disease and severe systemic
        atherosclerosis.\";\nRL   Eur. J. Clin. Invest. 33:216-222(2003).\nRN   [70]\nRP
        \  VARIANT LPL DEFICIENCY SER-318, AND VARIANT ASN-36.\nRX   PubMed=12966036;
        DOI=10.1093/hmg/ddg314;\nRA   Morabia A., Cayanis E., Costanza M.C., Ross
        B.M., Flaherty M.S.,\nRA   Alvin G.B., Das K., Gilliam T.C.;\nRT   \"Association
        of extreme blood lipid profile phenotypic variation with\nRT   11 reverse
        cholesterol transport genes and 10 non-genetic\nRT   cardiovascular disease
        risk factors.\";\nRL   Hum. Mol. Genet. 12:2733-2743(2003).\nRN   [71]\nRP
        \  VARIANT LPL DEFICIENCY VAL-201.\nRX   PubMed=14984478; DOI=10.1111/j.0009-9163.2004.00205.x;\nRA
        \  Abifadel M., Jambart S., Allard D., Rabes J.-P., Varret M., Derre A.,\nRA
        \  Chouery E., Salem N., Junien C., Aydenian H., Boileau C.;\nRT   \"Identification
        of the first Lebanese mutation in the LPL gene and\nRT   description of a
        rapid detection method.\";\nRL   Clin. Genet. 65:158-161(2004).\nRN   [72]\nRP
        \  VARIANTS LPL DEFICIENCY GLU-215 AND ARG-328.\nRX   PubMed=15185149; DOI=10.1007/s00431-004-1474-1;\nRA
        \  Kavazarakis E., Stabouli S., Gourgiotis D., Roumeliotou K.,\nRA   Traeger-Synodinos
        J., Bossios A., Fretzayas A., Kanavakis E.;\nRT   \"Severe hypertriglyceridaemia
        in a Greek infant: a clinical,\nRT   biochemical and genetic study.\";\nRL
        \  Eur. J. Pediatr. 163:462-466(2004).\nRN   [73]\nRP   VARIANTS LPL DEFICIENCY
        SER-70; ARG-132; VAL-181; GLU-215; THR-221;\nRP   ARG-225; ALA-227; GLU-231;
        CYS-270; HIS-270; THR-288; LEU-297;\nRP   ARG-305; PHE-330 AND THR-361.\nRX
        \  PubMed=15256764; DOI=10.5551/jat.11.131;\nRG   The research committee on
        primary hyperlipidemia of the ministry of health and welfare of Japan;\nRA
        \  Maruyama T., Yamashita S., Matsuzawa Y., Bujo H., Takahashi K.,\nRA   Saito
        Y., Ishibashi S., Ohashi K., Shionoiri F., Gotoda T., Yamada N.,\nRA   Kita
        T.;\nRT   \"Mutations in Japanese subjects with primary hyperlipidemia --
        results\nRT   from the Research Committee of the Ministry of Health and Welfare
        of\nRT   Japan since 1996.\";\nRL   J. Atheroscler. Thromb. 11:131-145(2004).\nRN
        \  [74]\nRP   VARIANTS LPL DEFICIENCY GLU-186; GLU-215 AND THR-221.\nRX   PubMed=15877202;
        DOI=10.1007/s10545-005-7060-5;\nRA   Santer R., Gokcay G., Demirkol M., Gal
        A., Lukacs Z.;\nRT   \"Hyperchylomicronaemia due to lipoprotein lipase deficiency
        as a cause\nRT   of false-positive newborn screening for biotinidase deficiency.\";\nRL
        \  J. Inherit. Metab. Dis. 28:137-140(2005).\nRN   [75]\nRP   VARIANT LPL
        DEFICIENCY ARG-404, CHARACTERIZATION OF VARIANT LPL\nRP   DEFICIENCY ARG-404,
        FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR\nRP   LOCATION.\nRX   PubMed=27578112;
        DOI=10.1016/j.jacl.2016.02.015;\nRA   Pingitore P., Lepore S.M., Pirazzi C.,
        Mancina R.M., Motta B.M.,\nRA   Valenti L., Berge K.E., Retterstoel K., Leren
        T.P., Wiklund O.,\nRA   Romeo S.;\nRT   \"Identification and characterization
        of two novel mutations in the LPL\nRT   gene causing type I hyperlipoproteinemia.\";\nRL
        \  J. Clin. Lipidol. 10:816-823(2016).\nCC   -!- FUNCTION: The primary function
        of this lipase is the hydrolysis of\nCC       triglycerides of circulating
        chylomicrons and very low density\nCC       lipoproteins (VLDL) (PubMed:27578112).
        Binding to heparin sulfate\nCC       proteogylcans at the cell surface is
        vital to the function. The\nCC       apolipoprotein, APOC2, acts as a coactivator
        of LPL activity in\nCC       the presence of lipids on the luminal surface
        of vascular\nCC       endothelium (By similarity). {ECO:0000250,\nCC       ECO:0000269|PubMed:11342582,
        ECO:0000269|PubMed:27578112}.\nCC   -!- CATALYTIC ACTIVITY: Triacylglycerol
        + H(2)O = diacylglycerol + a\nCC       carboxylate. {ECO:0000269|PubMed:11342582,\nCC
        \      ECO:0000269|PubMed:27578112}.\nCC   -!- SUBUNIT: Homodimer (By similarity).
        Interacts with APOC2; the\nCC       interaction activates LPL activity in
        the presence of lipids (By\nCC       similarity). Interacts with GPIHBP1 (PubMed:17997385).
        Interacts\nCC       with SEL1L and LMF1 (PubMed:25066055).\nCC       {ECO:0000250|UniProtKB:P11151,
        ECO:0000250|UniProtKB:P11152,\nCC       ECO:0000269|PubMed:17997385, ECO:0000269|PubMed:25066055}.\nCC
        \  -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250}; Lipid-anchor,\nCC
        \      GPI-anchor {ECO:0000250}. Secreted {ECO:0000269|PubMed:2340307,\nCC
        \      ECO:0000269|PubMed:27578112}. Note=Locates to the plasma membrane\nCC
        \      of microvilli of hepatocytes with triacyl-glycerol-rich\nCC       lipoproteins
        (TRL). Some of the bound LPL is then internalized and\nCC       located inside
        non-coated endocytic vesicles (By similarity).\nCC       {ECO:0000250}.\nCC
        \  -!- PTM: Tyrosine nitration after lipopolysaccharide (LPS) challenge\nCC
        \      down-regulates the lipase activity.\nCC       {ECO:0000250|UniProtKB:Q06000}.\nCC
        \  -!- DISEASE: Lipoprotein lipase deficiency (LPL deficiency)\nCC       [MIM:238600]:
        Recessive disorder usually manifesting in childhood.\nCC       On a normal
        diet, patients often present with abdominal pain,\nCC       hepatosplenomegaly,
        lipemia retinalis, eruptive xanthomata, and\nCC       massive hypertriglyceridemia,
        sometimes complicated with acute\nCC       pancreatitis. {ECO:0000269|PubMed:10660334,\nCC
        \      ECO:0000269|PubMed:10787434, ECO:0000269|PubMed:11068186,\nCC       ECO:0000269|PubMed:11099402,
        ECO:0000269|PubMed:11134145,\nCC       ECO:0000269|PubMed:11441134, ECO:0000269|PubMed:12204001,\nCC
        \      ECO:0000269|PubMed:12641539, ECO:0000269|PubMed:12966036,\nCC       ECO:0000269|PubMed:1400331,
        ECO:0000269|PubMed:1479292,\nCC       ECO:0000269|PubMed:14984478, ECO:0000269|PubMed:15185149,\nCC
        \      ECO:0000269|PubMed:1521525, ECO:0000269|PubMed:15256764,\nCC       ECO:0000269|PubMed:15877202,
        ECO:0000269|PubMed:1598907,\nCC       ECO:0000269|PubMed:1619366, ECO:0000269|PubMed:1639392,\nCC
        \      ECO:0000269|PubMed:1674945, ECO:0000269|PubMed:1702428,\nCC       ECO:0000269|PubMed:1730727,
        ECO:0000269|PubMed:1752947,\nCC       ECO:0000269|PubMed:1907278, ECO:0000269|PubMed:1969408,\nCC
        \      ECO:0000269|PubMed:1975597, ECO:0000269|PubMed:2010533,\nCC       ECO:0000269|PubMed:2038366,
        ECO:0000269|PubMed:2110364,\nCC       ECO:0000269|PubMed:2121025, ECO:0000269|PubMed:27578112,\nCC
        \      ECO:0000269|PubMed:7647785, ECO:0000269|PubMed:7806969,\nCC       ECO:0000269|PubMed:7906986,
        ECO:0000269|PubMed:7912254,\nCC       ECO:0000269|PubMed:7999071, ECO:0000269|PubMed:8077845,\nCC
        \      ECO:0000269|PubMed:8096693, ECO:0000269|PubMed:8135797,\nCC       ECO:0000269|PubMed:8288243,
        ECO:0000269|PubMed:8301230,\nCC       ECO:0000269|PubMed:8325986, ECO:0000269|PubMed:8486765,\nCC
        \      ECO:0000269|PubMed:8728326, ECO:0000269|PubMed:8778602,\nCC       ECO:0000269|PubMed:8858123,
        ECO:0000269|PubMed:8872057,\nCC       ECO:0000269|PubMed:8956048, ECO:0000269|PubMed:8956052,\nCC
        \      ECO:0000269|PubMed:9279761, ECO:0000269|PubMed:9298816,\nCC       ECO:0000269|PubMed:9498099,
        ECO:0000269|PubMed:9662394,\nCC       ECO:0000269|PubMed:9714430, ECO:0000269|PubMed:9719626}.
        Note=The\nCC       disease is caused by mutations affecting the gene represented
        in\nCC       this entry.\nCC   -!- SIMILARITY: Belongs to the AB hydrolase
        superfamily. Lipase\nCC       family. {ECO:0000305}.\nCC   -!- WEB RESOURCE:
        Name=SHMPD; Note=The Singapore human mutation and\nCC       polymorphism database;\nCC
        \      URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=LPL\";\nCC
        \  -!- WEB RESOURCE: Name=Wikipedia; Note=Lipoprotein lipase entry;\nCC       URL=\"https://en.wikipedia.org/wiki/Lipoprotein_lipase\";\nCC
        \  -----------------------------------------------------------------------\nCC
        \  Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms\nCC
        \  Distributed under the Creative Commons Attribution-NoDerivs License\nCC
        \  -----------------------------------------------------------------------\nDR
        \  EMBL; M15856; AAB59536.1; -; mRNA.\nDR   EMBL; X14390; CAA32564.1; -; mRNA.\nDR
        \  EMBL; X54516; CAA38372.1; -; mRNA.\nDR   EMBL; M76722; AAA59528.1; -; Genomic_DNA.\nDR
        \  EMBL; S76076; AAB21000.1; -; Genomic_DNA.\nDR   EMBL; S76077; AAB20999.1;
        -; Genomic_DNA.\nDR   EMBL; BT006726; AAP35372.1; -; mRNA.\nDR   EMBL; AK312311;
        BAG35236.1; -; mRNA.\nDR   EMBL; CH471080; EAW63764.1; -; Genomic_DNA.\nDR
        \  EMBL; BC011353; AAH11353.1; -; mRNA.\nDR   EMBL; X68111; CAA48230.1; -;
        Genomic_DNA.\nDR   CCDS; CCDS6012.1; -.\nDR   PIR; A26082; LIHUL.\nDR   RefSeq;
        NP_000228.1; NM_000237.2.\nDR   UniGene; Hs.180878; -.\nDR   ProteinModelPortal;
        P06858; -.\nDR   SMR; P06858; -.\nDR   BioGrid; 110205; 18.\nDR   IntAct;
        P06858; 14.\nDR   MINT; MINT-1369348; -.\nDR   STRING; 9606.ENSP00000309757;
        -.\nDR   BindingDB; P06858; -.\nDR   ChEMBL; CHEMBL2060; -.\nDR   DrugBank;
        DB09278; Activated charcoal.\nDR   DrugBank; DB06439; Tyloxapol.\nDR   SwissLipids;
        SLP:000000568; -.\nDR   ESTHER; human-LPL; Lipoprotein_Lipase.\nDR   iPTMnet;
        P06858; -.\nDR   PhosphoSitePlus; P06858; -.\nDR   BioMuta; LPL; -.\nDR   DMDM;
        126314; -.\nDR   EPD; P06858; -.\nDR   MaxQB; P06858; -.\nDR   PaxDb; P06858;
        -.\nDR   PeptideAtlas; P06858; -.\nDR   PRIDE; P06858; -.\nDR   DNASU; 4023;
        -.\nDR   Ensembl; ENST00000311322; ENSP00000309757; ENSG00000175445.\nDR   GeneID;
        4023; -.\nDR   KEGG; hsa:4023; -.\nDR   UCSC; uc003wzk.5; human.\nDR   CTD;
        4023; -.\nDR   DisGeNET; 4023; -.\nDR   GeneCards; LPL; -.\nDR   GeneReviews;
        LPL; -.\nDR   HGNC; HGNC:6677; LPL.\nDR   HPA; HPA048749; -.\nDR   MalaCards;
        LPL; -.\nDR   MIM; 238600; phenotype.\nDR   MIM; 609708; gene.\nDR   neXtProt;
        NX_P06858; -.\nDR   OpenTargets; ENSG00000175445; -.\nDR   Orphanet; 309015;
        Familial lipoprotein lipase deficiency.\nDR   Orphanet; 70470; Hyperlipoproteinemia
        type 5.\nDR   PharmGKB; PA232; -.\nDR   eggNOG; ENOG410IJUA; Eukaryota.\nDR
        \  eggNOG; ENOG4111GMM; LUCA.\nDR   GeneTree; ENSGT00760000119069; -.\nDR
        \  HOGENOM; HOG000038553; -.\nDR   HOVERGEN; HBG002259; -.\nDR   InParanoid;
        P06858; -.\nDR   KO; K01059; -.\nDR   OMA; ESVANCH; -.\nDR   OrthoDB; EOG091G052B;
        -.\nDR   PhylomeDB; P06858; -.\nDR   TreeFam; TF324997; -.\nDR   BRENDA; 3.1.1.34;
        2681.\nDR   Reactome; R-HSA-174800; Chylomicron-mediated lipid transport.\nDR
        \  Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.\nDR
        \  Reactome; R-HSA-975634; Retinoid metabolism and transport.\nDR   SIGNOR;
        P06858; -.\nDR   GeneWiki; Lipoprotein_lipase; -.\nDR   GenomeRNAi; 4023;
        -.\nDR   PRO; PR:P06858; -.\nDR   Proteomes; UP000005640; Chromosome 8.\nDR
        \  Bgee; ENSG00000175445; -.\nDR   CleanEx; HS_LPL; -.\nDR   ExpressionAtlas;
        P06858; baseline and differential.\nDR   Genevisible; P06858; HS.\nDR   GO;
        GO:0031225; C:anchored component of membrane; IEA:UniProtKB-KW.\nDR   GO;
        GO:0009986; C:cell surface; IEA:Ensembl.\nDR   GO; GO:0042627; C:chylomicron;
        IEA:UniProtKB-KW.\nDR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.\nDR
        \  GO; GO:0031012; C:extracellular matrix; IEA:Ensembl.\nDR   GO; GO:0005576;
        C:extracellular region; TAS:Reactome.\nDR   GO; GO:0005615; C:extracellular
        space; IDA:UniProtKB.\nDR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.\nDR
        \  GO; GO:0034361; C:very-low-density lipoprotein particle; IEA:UniProtKB-KW.\nDR
        \  GO; GO:0034185; F:apolipoprotein binding; IPI:BHF-UCL.\nDR   GO; GO:0008201;
        F:heparin binding; IDA:UniProtKB.\nDR   GO; GO:0004465; F:lipoprotein lipase
        activity; IDA:UniProtKB.\nDR   GO; GO:0004620; F:phospholipase activity; ISS:BHF-UCL.\nDR
        \  GO; GO:0005102; F:receptor binding; IPI:BHF-UCL.\nDR   GO; GO:0017129;
        F:triglyceride binding; IEA:Ensembl.\nDR   GO; GO:0004806; F:triglyceride
        lipase activity; IDA:BHF-UCL.\nDR   GO; GO:0042632; P:cholesterol homeostasis;
        IMP:BHF-UCL.\nDR   GO; GO:0034371; P:chylomicron remodeling; IC:BHF-UCL.\nDR
        \  GO; GO:0006633; P:fatty acid biosynthetic process; IDA:BHF-UCL.\nDR   GO;
        GO:0042157; P:lipoprotein metabolic process; TAS:Reactome.\nDR   GO; GO:0055096;
        P:low-density lipoprotein particle mediated signaling; IMP:BHF-UCL.\nDR   GO;
        GO:0006644; P:phospholipid metabolic process; ISS:BHF-UCL.\nDR   GO; GO:0090197;
        P:positive regulation of chemokine secretion; IMP:BHF-UCL.\nDR   GO; GO:0010886;
        P:positive regulation of cholesterol storage; IMP:BHF-UCL.\nDR   GO; GO:0050729;
        P:positive regulation of inflammatory response; IC:BHF-UCL.\nDR   GO; GO:0010744;
        P:positive regulation of macrophage derived foam cell differentiation; IC:BHF-UCL.\nDR
        \  GO; GO:0010890; P:positive regulation of sequestering of triglyceride;
        IMP:BHF-UCL.\nDR   GO; GO:0009409; P:response to cold; IEA:Ensembl.\nDR   GO;
        GO:0042493; P:response to drug; IEA:Ensembl.\nDR   GO; GO:0009749; P:response
        to glucose; ISS:AgBase.\nDR   GO; GO:0001523; P:retinoid metabolic process;
        TAS:Reactome.\nDR   GO; GO:0019432; P:triglyceride biosynthetic process; IDA:UniProtKB.\nDR
        \  GO; GO:0019433; P:triglyceride catabolic process; IDA:UniProtKB.\nDR   GO;
        GO:0070328; P:triglyceride homeostasis; IGI:BHF-UCL.\nDR   GO; GO:0006641;
        P:triglyceride metabolic process; ISS:BHF-UCL.\nDR   GO; GO:0034372; P:very-low-density
        lipoprotein particle remodeling; IDA:BHF-UCL.\nDR   CDD; cd00707; Pancreat_lipase_like;
        1.\nDR   Gene3D; 2.60.60.20; -; 1.\nDR   Gene3D; 3.40.50.1820; -; 1.\nDR   InterPro;
        IPR029058; AB_hydrolase.\nDR   InterPro; IPR013818; Lipase/vitellogenin.\nDR
        \  InterPro; IPR016272; Lipase_LIPH.\nDR   InterPro; IPR033906; Lipase_N.\nDR
        \  InterPro; IPR002330; Lipo_Lipase.\nDR   InterPro; IPR001024; PLAT/LH2_dom.\nDR
        \  InterPro; IPR000734; TAG_lipase.\nDR   PANTHER; PTHR11610; PTHR11610; 1.\nDR
        \  PANTHER; PTHR11610:SF122; PTHR11610:SF122; 1.\nDR   Pfam; PF00151; Lipase;
        1.\nDR   Pfam; PF01477; PLAT; 1.\nDR   PIRSF; PIRSF000865; Lipoprotein_lipase_LIPH;
        1.\nDR   PRINTS; PR00822; LIPOLIPASE.\nDR   PRINTS; PR00821; TAGLIPASE.\nDR
        \  SMART; SM00308; LH2; 1.\nDR   SUPFAM; SSF49723; SSF49723; 1.\nDR   SUPFAM;
        SSF53474; SSF53474; 1.\nDR   TIGRFAMs; TIGR03230; lipo_lipase; 1.\nDR   PROSITE;
        PS00120; LIPASE_SER; 1.\nDR   PROSITE; PS50095; PLAT; 1.\nPE   1: Evidence
        at protein level;\nKW   Cell membrane; Chylomicron; Complete proteome;\nKW
        \  Direct protein sequencing; Disease mutation; Disulfide bond;\nKW   Glycoprotein;
        GPI-anchor; Heparin-binding; Hydrolase; Hyperlipidemia;\nKW   Lipid degradation;
        Lipid metabolism; Lipoprotein; Membrane; Nitration;\nKW   Polymorphism; Reference
        proteome; Secreted; Signal; VLDL.\nFT   SIGNAL        1     27       {ECO:0000269|PubMed:2340307}.\nFT
        \  CHAIN        28    475       Lipoprotein lipase.\nFT                                /FTId=PRO_0000017775.\nFT
        \  DOMAIN      341    464       PLAT. {ECO:0000255|PROSITE-\nFT                                ProRule:PRU00152}.\nFT
        \  REGION      346    441       Heparin-binding. {ECO:0000250}.\nFT   ACT_SITE
        \   159    159       Nucleophile.\nFT   ACT_SITE    183    183       Charge
        relay system.\nFT   ACT_SITE    268    268       Charge relay system.\nFT
        \  MOD_RES     121    121       Nitrated tyrosine.\nFT                                {ECO:0000250|UniProtKB:Q06000}.\nFT
        \  MOD_RES     191    191       Nitrated tyrosine.\nFT                                {ECO:0000250|UniProtKB:Q06000}.\nFT
        \  MOD_RES     343    343       Nitrated tyrosine.\nFT                                {ECO:0000250|UniProtKB:Q06000}.\nFT
        \  CARBOHYD     70     70       N-linked (GlcNAc...) asparagine.\nFT                                {ECO:0000269|PubMed:18780401}.\nFT
        \  CARBOHYD    386    386       N-linked (GlcNAc...) asparagine.\nFT                                {ECO:0000255}.\nFT
        \  DISULFID     54     67       {ECO:0000255|PROSITE-ProRule:PRU00152}.\nFT
        \  DISULFID    243    266       {ECO:0000255|PROSITE-ProRule:PRU00152}.\nFT
        \  DISULFID    291    310       {ECO:0000255|PROSITE-ProRule:PRU00152}.\nFT
        \  DISULFID    302    305       {ECO:0000255|PROSITE-ProRule:PRU00152}.\nFT
        \  DISULFID    445    465       {ECO:0000255|PROSITE-ProRule:PRU00152}.\nFT
        \  VARIANT      36     36       D -> N (in LPL deficiency; has\nFT                                approximately
        80% of the specific\nFT                                activity of wild-type
        enzyme;\nFT                                dbSNP:rs1801177).\nFT                                {ECO:0000269|PubMed:12966036,\nFT
        \                               ECO:0000269|PubMed:8728326,\nFT                                ECO:0000269|PubMed:8872057,\nFT
        \                               ECO:0000269|PubMed:9719626}.\nFT                                /FTId=VAR_011948.\nFT
        \  VARIANT      70     70       N -> S (in LPL deficiency; produces an\nFT
        \                               inactive protein which is not secreted\nFT
        \                               into the media).\nFT                                {ECO:0000269|PubMed:15256764,\nFT
        \                               ECO:0000269|PubMed:7999071}.\nFT                                /FTId=VAR_057914.\nFT
        \  VARIANT      71     71       H -> Q (in dbSNP:rs11542065).\nFT                                /FTId=VAR_049819.\nFT
        \  VARIANT      96     96       V -> L (in LPL deficiency; gives rise to\nFT
        \                               a 80% decrease in specific catalytic\nFT                                activity;
        dbSNP:rs373088068).\nFT                                {ECO:0000269|PubMed:7912254}.\nFT
        \                               /FTId=VAR_057915.\nFT   VARIANT      98     98
        \      A -> T (in LPL deficiency; decreases the\nFT                                specific
        activity of the enzyme; reduces\nFT                                the secretion
        of the mutant protein\nFT                                significantly; the
        total LPL mass is\nFT                                reduced compared to that
        of the wild-type\nFT                                construct; dbSNP:rs145657341).\nFT
        \                               {ECO:0000269|PubMed:12204001}.\nFT                                /FTId=VAR_057916.\nFT
        \  VARIANT     102    102       R -> S (in LPL deficiency;\nFT                                dbSNP:rs118204073).\nFT
        \                               {ECO:0000269|PubMed:8325986}.\nFT                                /FTId=VAR_004211.\nFT
        \  VARIANT     113    113       W -> G (in LPL deficiency).\nFT                                /FTId=VAR_004212.\nFT
        \  VARIANT     113    113       W -> R (in LPL deficiency;\nFT                                dbSNP:rs118204069).\nFT
        \                               {ECO:0000269|PubMed:1479292,\nFT                                ECO:0000269|PubMed:1598907}.\nFT
        \                               /FTId=VAR_004213.\nFT   VARIANT     128    128
        \      T -> A (in LPL deficiency).\nFT                                {ECO:0000269|PubMed:8778602,\nFT
        \                               ECO:0000269|PubMed:9279761}.\nFT                                /FTId=VAR_057917.\nFT
        \  VARIANT     132    132       G -> R (in LPL deficiency; synthesized as\nFT
        \                               a catalytically inactive form).\nFT                                {ECO:0000269|PubMed:11099402,\nFT
        \                               ECO:0000269|PubMed:15256764}.\nFT                                /FTId=VAR_057918.\nFT
        \  VARIANT     163    163       H -> R (in LPL deficiency).\nFT                                {ECO:0000269|PubMed:1479292}.\nFT
        \                               /FTId=VAR_004214.\nFT   VARIANT     169    169
        \      G -> E (in LPL deficiency; loss of\nFT                                activity;
        dbSNP:rs118204063).\nFT                                {ECO:0000269|PubMed:2010533}.\nFT
        \                               /FTId=VAR_004215.\nFT   VARIANT     181    181
        \      G -> S (in LPL deficiency).\nFT                                {ECO:0000269|PubMed:8301230}.\nFT
        \                               /FTId=VAR_004216.\nFT   VARIANT     181    181
        \      G -> V (in LPL deficiency; synthesized as\nFT                                a
        catalytically inactive form).\nFT                                {ECO:0000269|PubMed:11441134,\nFT
        \                               ECO:0000269|PubMed:15256764}.\nFT                                /FTId=VAR_057919.\nFT
        \  VARIANT     183    183       D -> G (in LPL deficiency; lacks both\nFT
        \                               triolein and tributyrin esterase\nFT                                activities;
        dbSNP:rs118204064).\nFT                                {ECO:0000269|PubMed:1371284,\nFT
        \                               ECO:0000269|PubMed:1730727,\nFT                                ECO:0000269|PubMed:1907278}.\nFT
        \                               /FTId=VAR_004217.\nFT   VARIANT     183    183
        \      D -> H (in LPL deficiency;\nFT                                dbSNP:rs781614031).\nFT
        \                               {ECO:0000269|PubMed:9279761}.\nFT                                /FTId=VAR_057920.\nFT
        \  VARIANT     183    183       D -> N (in LPL deficiency; lacks both\nFT
        \                               triolein and tributyrin esterase\nFT                                activities).
        {ECO:0000269|PubMed:1371284,\nFT                                ECO:0000269|PubMed:1730727}.\nFT
        \                               /FTId=VAR_004218.\nFT   VARIANT     184    184
        \      P -> R (in LPL deficiency; Nijmegen; loss\nFT                                of
        activity).\nFT                                {ECO:0000269|PubMed:1521525}.\nFT
        \                               /FTId=VAR_004219.\nFT   VARIANT     185    185
        \      A -> T (in LPL deficiency; 3.2% of\nFT                                activity;
        dbSNP:rs748349562).\nFT                                /FTId=VAR_004220.\nFT
        \  VARIANT     186    186       G -> E (in LPL deficiency).\nFT                                {ECO:0000269|PubMed:15877202}.\nFT
        \                               /FTId=VAR_057921.\nFT   VARIANT     190    190
        \      E -> G (in LPL deficiency).\nFT                                {ECO:0000269|PubMed:8956052}.\nFT
        \                               /FTId=VAR_057922.\nFT   VARIANT     199    199
        \      S -> C (in LPL deficiency; mild\nFT                                hypertriglyceridemia;
        partial activity;\nFT                                dbSNP:rs118204072).\nFT
        \                               {ECO:0000269|PubMed:8077845,\nFT                                ECO:0000269|PubMed:8486765}.\nFT
        \                               /FTId=VAR_004221.\nFT   VARIANT     201    201
        \      D -> V (in LPL deficiency).\nFT                                {ECO:0000269|PubMed:14984478}.\nFT
        \                               /FTId=VAR_057923.\nFT   VARIANT     203    203
        \      A -> T (in LPL deficiency; Bethesda; loss\nFT                                of
        activity and abnormal heparin binding;\nFT                                dbSNP:rs118204056).\nFT
        \                               {ECO:0000269|PubMed:2110364}.\nFT                                /FTId=VAR_004222.\nFT
        \  VARIANT     207    207       D -> E (in LPL deficiency;\nFT                                dbSNP:rs118204076).\nFT
        \                               {ECO:0000269|PubMed:8288243}.\nFT                                /FTId=VAR_004223.\nFT
        \  VARIANT     208    208       V -> I (in LPL deficiency; decreases the\nFT
        \                               specific activity of the enzyme; has a\nFT
        \                               mild effect on the secretion of the\nFT                                mutant
        enzyme; the total LPL mass is\nFT                                reduced compared
        to that of the wild-type\nFT                                construct; dbSNP:rs568397156).\nFT
        \                               {ECO:0000269|PubMed:12204001}.\nFT                                /FTId=VAR_057924.\nFT
        \  VARIANT     210    210       H -> D (in LPL deficiency; complete loss\nFT
        \                               of enzyme activity).\nFT                                {ECO:0000269|PubMed:10787434}.\nFT
        \                               /FTId=VAR_057925.\nFT   VARIANT     210    210
        \      H -> Q (in LPL deficiency; loss of\nFT                                activity).\nFT
        \                               /FTId=VAR_004224.\nFT   VARIANT     215    215
        \      G -> E (in LPL deficiency; loss of\nFT                                activity;
        dbSNP:rs118204057).\nFT                                {ECO:0000269|PubMed:10660334,\nFT
        \                               ECO:0000269|PubMed:1479292,\nFT                                ECO:0000269|PubMed:15185149,\nFT
        \                               ECO:0000269|PubMed:15256764,\nFT                                ECO:0000269|PubMed:15877202,\nFT
        \                               ECO:0000269|PubMed:1619366,\nFT                                ECO:0000269|PubMed:1969408,\nFT
        \                               ECO:0000269|PubMed:1975597,\nFT                                ECO:0000269|PubMed:7912254,\nFT
        \                               ECO:0000269|PubMed:8778602,\nFT                                ECO:0000269|PubMed:8956052,\nFT
        \                               ECO:0000269|PubMed:9279761}.\nFT                                /FTId=VAR_004225.\nFT
        \  VARIANT     215    215       G -> R (in LPL deficiency).\nFT                                {ECO:0000269|PubMed:8778602,\nFT
        \                               ECO:0000269|PubMed:9279761}.\nFT                                /FTId=VAR_057926.\nFT
        \  VARIANT     220    220       S -> R (in LPL deficiency; 2.0% of\nFT                                activity;
        dbSNP:rs757546424).\nFT                                /FTId=VAR_004226.\nFT
        \  VARIANT     221    221       I -> T (in LPL deficiency; loss of\nFT                                activity;
        dbSNP:rs118204061).\nFT                                {ECO:0000269|PubMed:1479292,\nFT
        \                               ECO:0000269|PubMed:15256764,\nFT                                ECO:0000269|PubMed:15877202,\nFT
        \                               ECO:0000269|PubMed:1674945,\nFT                                ECO:0000269|PubMed:1702428}.\nFT
        \                               /FTId=VAR_004227.\nFT   VARIANT     222    222
        \      G -> E (in LPL deficiency;\nFT                                dbSNP:rs118204075).\nFT
        \                               {ECO:0000269|PubMed:1400331}.\nFT                                /FTId=VAR_004228.\nFT
        \  VARIANT     225    225       K -> R (in LPL deficiency).\nFT                                {ECO:0000269|PubMed:15256764}.\nFT
        \                               /FTId=VAR_057927.\nFT   VARIANT     227    227
        \      V -> A (in LPL deficiency;\nFT                                dbSNP:rs528243561).\nFT
        \                               {ECO:0000269|PubMed:15256764}.\nFT                                /FTId=VAR_057928.\nFT
        \  VARIANT     231    231       D -> E (in LPL deficiency; loss of\nFT                                activity;
        dbSNP:rs118204067).\nFT                                {ECO:0000269|PubMed:11099402,\nFT
        \                               ECO:0000269|PubMed:15256764,\nFT                                ECO:0000269|PubMed:1752947}.\nFT
        \                               /FTId=VAR_004229.\nFT   VARIANT     232    232
        \      I -> S (in LPL deficiency;\nFT                                dbSNP:rs770601263).\nFT
        \                               {ECO:0000269|PubMed:1479292}.\nFT                                /FTId=VAR_004230.\nFT
        \  VARIANT     234    234       P -> L (in LPL deficiency; loss of\nFT                                activity;
        dbSNP:rs118204060).\nFT                                {ECO:0000269|PubMed:2038366,\nFT
        \                               ECO:0000269|PubMed:9279761}.\nFT                                /FTId=VAR_004231.\nFT
        \  VARIANT     243    243       C -> S (in LPL deficiency; loss of\nFT                                activity).
        {ECO:0000269|PubMed:1730727}.\nFT                                /FTId=VAR_004232.\nFT
        \  VARIANT     252    252       I -> T (in LPL deficiency;\nFT                                dbSNP:rs118204080).\nFT
        \                               {ECO:0000269|PubMed:9714430}.\nFT                                /FTId=VAR_057929.\nFT
        \  VARIANT     266    266       C -> W (in LPL deficiency;\nFT                                dbSNP:rs118204082).\nFT
        \                               {ECO:0000269|PubMed:11134145}.\nFT                                /FTId=VAR_057930.\nFT
        \  VARIANT     270    270       R -> C (in LPL deficiency;\nFT                                dbSNP:rs118204077).\nFT
        \                               {ECO:0000269|PubMed:15256764,\nFT                                ECO:0000269|PubMed:7906986,\nFT
        \                               ECO:0000269|PubMed:8778602,\nFT                                ECO:0000269|PubMed:9279761}.\nFT
        \                               /FTId=VAR_057931.\nFT   VARIANT     270    270
        \      R -> H (in LPL deficiency; loss of\nFT                                activity;
        dbSNP:rs118204062).\nFT                                {ECO:0000269|PubMed:15256764,\nFT
        \                               ECO:0000269|PubMed:1619366,\nFT                                ECO:0000269|PubMed:1702428,\nFT
        \                               ECO:0000269|PubMed:1752947,\nFT                                ECO:0000269|PubMed:7906986,\nFT
        \                               ECO:0000269|PubMed:9714430}.\nFT                                /FTId=VAR_004233.\nFT
        \  VARIANT     271    271       S -> T (in LPL deficiency;\nFT                                dbSNP:rs28934893).\nFT
        \                               {ECO:0000269|PubMed:2121025}.\nFT                                /FTId=VAR_004234.\nFT
        \  VARIANT     277    277       D -> N (in LPL deficiency; 5% of full\nFT
        \                               activity; dbSNP:rs118204068).\nFT                                {ECO:0000269|PubMed:1619366,\nFT
        \                               ECO:0000269|PubMed:1639392,\nFT                                ECO:0000269|PubMed:8778602,\nFT
        \                               ECO:0000269|PubMed:8956048,\nFT                                ECO:0000269|PubMed:9279761}.\nFT
        \                               /FTId=VAR_004235.\nFT   VARIANT     278    278
        \      S -> C (in LPL deficiency).\nFT                                /FTId=VAR_004236.\nFT
        \  VARIANT     279    279       L -> R (in LPL deficiency; decreases the\nFT
        \                               specific activity of the enzyme; the\nFT                                total
        LPL mass is reduced compared to\nFT                                that of
        the wild-type construct;\nFT                                dbSNP:rs35414700).\nFT
        \                               {ECO:0000269|PubMed:12204001,\nFT                                ECO:0000269|PubMed:8077845}.\nFT
        \                               /FTId=VAR_057932.\nFT   VARIANT     279    279
        \      L -> V (in LPL deficiency; decreases the\nFT                                specific
        activity of the enzyme; the\nFT                                total LPL mass
        is reduced compared to\nFT                                that of the wild-type
        construct;\nFT                                dbSNP:rs371282890).\nFT                                {ECO:0000269|PubMed:12204001}.\nFT
        \                               /FTId=VAR_057933.\nFT   VARIANT     286    286
        \      S -> G (in LPL deficiency).\nFT                                {ECO:0000269|PubMed:10660334}.\nFT
        \                               /FTId=VAR_004237.\nFT   VARIANT     286    286
        \      S -> R (in LPL deficiency).\nFT                                {ECO:0000269|PubMed:9298816}.\nFT
        \                               /FTId=VAR_004238.\nFT   VARIANT     288    288
        \      A -> T (in LPL deficiency; the LPL mass\nFT                                level
        is approximately 67% of the normal;\nFT                                the
        activity is 32% of the nornal;\nFT                                dbSNP:rs1800011).\nFT
        \                               {ECO:0000269|PubMed:15256764,\nFT                                ECO:0000269|PubMed:8077845,\nFT
        \                               ECO:0000269|PubMed:9719626}.\nFT                                /FTId=VAR_011949.\nFT
        \  VARIANT     289    289       Y -> H (in LPL deficiency; no enzyme\nFT                                activity).
        {ECO:0000269|PubMed:8728326}.\nFT                                /FTId=VAR_057934.\nFT
        \  VARIANT     297    297       F -> L (in LPL deficiency and\nFT                                hyperlipidemia;
        synthesized as a\nFT                                catalytically inactive
        form; total amount\nFT                                is almost equal to that
        of the normal\nFT                                enzyme; non-releasable by
        heparin due to\nFT                                the abnormal structure of
        the mutant\nFT                                protein). {ECO:0000269|PubMed:11068186,\nFT
        \                               ECO:0000269|PubMed:15256764}.\nFT                                /FTId=VAR_057935.\nFT
        \  VARIANT     303    303       L -> F (in LPL deficiency; approximately\nFT
        \                               6% of normal LPL activity and 40% of LPL\nFT
        \                               mass are detected in the patient's\nFT                                postheparin
        plasma; results in the\nFT                                production of a
        functionally inactive\nFT                                enzyme). {ECO:0000269|PubMed:12641539}.\nFT
        \                               /FTId=VAR_057936.\nFT   VARIANT     305    305
        \      C -> R (in LPL deficiency;\nFT                                dbSNP:rs773235712).\nFT
        \                               {ECO:0000269|PubMed:15256764}.\nFT                                /FTId=VAR_057937.\nFT
        \  VARIANT     310    310       C -> Y (in LPL deficiency; decreases the\nFT
        \                               specific activity of the enzyme; reduces\nFT
        \                               the secretion of the mutant protein\nFT                                significantly;
        the total LPL mass is\nFT                                reduced compared
        to that of the wild-type\nFT                                construct).\nFT
        \                               {ECO:0000269|PubMed:12204001}.\nFT                                /FTId=VAR_057938.\nFT
        \  VARIANT     313    313       L -> P (in LPL deficiency).\nFT                                {ECO:0000269|PubMed:8778602}.\nFT
        \                               /FTId=VAR_057939.\nFT   VARIANT     318    318
        \      N -> S (in LPL deficiency; loss of\nFT                                activity;
        frequent mutation;\nFT                                dbSNP:rs268).\nFT                                {ECO:0000269|PubMed:12966036,\nFT
        \                               ECO:0000269|PubMed:15489334,\nFT                                ECO:0000269|PubMed:7647785,\nFT
        \                               ECO:0000269|PubMed:8077845,\nFT                                ECO:0000269|PubMed:8872057,\nFT
        \                               ECO:0000269|PubMed:9662394,\nFT                                ECO:0000269|PubMed:9719626,\nFT
        \                               ECO:0000269|Ref.5}.\nFT                                /FTId=VAR_004239.\nFT
        \  VARIANT     325    325       S -> R (in LPL deficiency; has no effect\nFT
        \                               on the specific activity of the enzyme;\nFT
        \                               has a mild effect on the secretion of the\nFT
        \                               mutant enzyme; the total LPL mass is\nFT                                reduced
        compared to that of the wild-type\nFT                                construct;
        dbSNP:rs761265900).\nFT                                {ECO:0000269|PubMed:12204001}.\nFT
        \                               /FTId=VAR_057940.\nFT   VARIANT     328    328
        \      M -> R (in LPL deficiency).\nFT                                {ECO:0000269|PubMed:15185149}.\nFT
        \                               /FTId=VAR_057941.\nFT   VARIANT     328    328
        \      M -> T (in LPL deficiency).\nFT                                /FTId=VAR_004240.\nFT
        \  VARIANT     330    330       L -> F (in LPL deficiency).\nFT                                {ECO:0000269|PubMed:15256764}.\nFT
        \                               /FTId=VAR_057942.\nFT   VARIANT     330    330
        \      L -> P (in LPL deficiency).\nFT                                /FTId=VAR_004241.\nFT
        \  VARIANT     361    361       A -> T (in LPL deficiency;\nFT                                dbSNP:rs118204071).\nFT
        \                               {ECO:0000269|PubMed:15256764,\nFT                                ECO:0000269|PubMed:8096693}.\nFT
        \                               /FTId=VAR_004242.\nFT   VARIANT     365    365
        \      S -> F (in LPL deficiency; increases the\nFT                                specific
        activity of the enzyme; has a\nFT                                mild effect
        on the secretion of the\nFT                                mutant enzyme;
        the total LPL mass is\nFT                                reduced compared
        to that of the wild-type\nFT                                construct; dbSNP:rs546542623).\nFT
        \                               {ECO:0000269|PubMed:12204001}.\nFT                                /FTId=VAR_057943.\nFT
        \  VARIANT     370    370       V -> M (in dbSNP:rs298).\nFT                                {ECO:0000269|PubMed:9662394}.\nFT
        \                               /FTId=VAR_011950.\nFT   VARIANT     379    379
        \      T -> A (in dbSNP:rs300).\nFT                                {ECO:0000269|PubMed:9662394}.\nFT
        \                               /FTId=VAR_011951.\nFT   VARIANT     392    392
        \      L -> V (in LPL deficiency; loss of\nFT                                activity;
        dbSNP:rs118204078).\nFT                                {ECO:0000269|PubMed:8135797}.\nFT
        \                               /FTId=VAR_004243.\nFT   VARIANT     404    404
        \      M -> R (in LPL deficiency; decreased\nFT                                protein
        secretion; loss of lipoprotein\nFT                                lipase activity).\nFT
        \                               {ECO:0000269|PubMed:27578112}.\nFT                                /FTId=VAR_077541.\nFT
        \  VARIANT     423    424       Missing (in LPL deficiency; affects the\nFT
        \                               protein folding).\nFT                                /FTId=VAR_004244.\nFT
        \  VARIANT     427    427       A -> T (in dbSNP:rs5934).\nFT                                {ECO:0000269|PubMed:10391209}.\nFT
        \                               /FTId=VAR_011952.\nFT   VARIANT     437    437
        \      E -> K (in LPL deficiency).\nFT                                {ECO:0000269|PubMed:8956048}.\nFT
        \                               /FTId=VAR_004245.\nFT   VARIANT     437    437
        \      E -> V (in LPL deficiency).\nFT                                {ECO:0000269|PubMed:7806969}.\nFT
        \                               /FTId=VAR_004246.\nFT   VARIANT     445    445
        \      C -> Y (in LPL deficiency; has 48% of\nFT                                normal
        activity in vitro; decreased\nFT                                levels of
        activity account for by the\nFT                                lower protein
        mass levels of the mutants\nFT                                rather than
        by decreased enzymatic\nFT                                activities; dbSNP:rs118204079).\nFT
        \                               {ECO:0000269|PubMed:8858123}.\nFT                                /FTId=VAR_057944.\nFT
        \  VARIANT     448    448       E -> K (in LPL deficiency; results in a\nFT
        \                               moderate reduction in catalytic activity;\nFT
        \                               dbSNP:rs149089920).\nFT                                {ECO:0000269|PubMed:9498099}.\nFT
        \                               /FTId=VAR_057945.\nFT   MUTAGEN     159    159
        \      S->G: Lacks both triolein and tributyrin\nFT                                esterase
        activities.\nFT                                {ECO:0000269|PubMed:1371284}.\nFT
        \  MUTAGEN     159    159       S->T: Lacks both triolein and tributyrin\nFT
        \                               esterase activities.\nFT                                {ECO:0000269|PubMed:1371284}.\nFT
        \  MUTAGEN     268    268       H->G: Lacks both triolein and tributyrin\nFT
        \                               esterase activities.\nFT                                {ECO:0000269|PubMed:1371284}.\nFT
        \  MUTAGEN     268    268       H->Q: Lacks both triolein and tributyrin\nFT
        \                               esterase activities.\nFT                                {ECO:0000269|PubMed:1371284}.\nSQ
        \  SEQUENCE   475 AA;  53162 MW;  FBD00FCD334FB8AA CRC64;\n     MESKALLVLT
        LAVWLQSLTA SRGGVAAADQ RRDFIDIESK FALRTPEDTA EDTCHLIPGV\n     AESVATCHFN HSSKTFMVIH
        GWTVTGMYES WVPKLVAALY KREPDSNVIV VDWLSRAQEH\n     YPVSAGYTKL VGQDVARFIN WMEEEFNYPL
        DNVHLLGYSL GAHAAGIAGS LTNKKVNRIT\n     GLDPAGPNFE YAEAPSRLSP DDADFVDVLH TFTRGSPGRS
        IGIQKPVGHV DIYPNGGTFQ\n     PGCNIGEAIR VIAERGLGDV DQLVKCSHER SIHLFIDSLL NEENPSKAYR
        CSSKEAFEKG\n     LCLSCRKNRC NNLGYEINKV RAKRSSKMYL KTRSQMPYKV FHYQVKIHFS GTESETHTNQ\n
        \    AFEISLYGTV AESENIPFTL PEVSTNKTYS FLIYTEVDIG ELLMLKLKWK SDSYFSWSDW\n     WSSPGFAIQK
        IRVKAGETQK KVIFCSREKV SHLQKGKAPA VFVKCHDKSL NKKSG\n//\n"}
    headers:
      Access-Control-Allow-Headers: ['origin, x-requested-with, content-type']
      Access-Control-Allow-Origin: ['*']
      Connection: [close]
      Content-Type: [text/plain;charset=ISO-8859-1]
      Date: ['Sat, 03 Jun 2017 23:33:51 GMT']
      Expires: ['Sun, 04 Jun 2017 23:33:52 GMT']
      Last-Modified: ['Wed, 10 May 2017 00:00:00 GMT']
      Server: [Apache-Coyote/1.1]
      Vary: [User-Agent, Accept-Encoding]
      X-Hosted-By: [European Bioinformatics Institute]
      X-Total-Results: ['1']
      X-UniProt-Release: ['2017_05']
    status: {code: 200, message: OK}
version: 1
